Shots:

• The company reveals results from the P-I/II (AK-OTOF-101) study of AK-OTOF (4.1E11 total vector genomes, single, unilateral intracochlear administration) for hearing loss evaluated by behavioral audiometry and auditory brainstem response (ABR)
• The results revealed hearing restoration within 30 days in the first patient and an 11yrs. old having hearing loss by birth. The hearing was restored at all tested frequencies, attaining a threshold range from 65-20 dB HL
• AK-OTOF (AAVAnc80-hOTOF), AAV-based gene therapy, aims at restoring hearing loss by transferring gene and durable expression of normal, functional otoferlin protein into the inner hair cells of the cochlea

Ref: Lilly | Image: Lilly

Related News:- Lilly to Acquire Akouos for ~$610M

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com